Digest Network Come funziona
Network
/
Società
Cu
Non verificato

Cure Rare Disease

Di cosa scriviamo

BiotecnologiaFarmaceuticaSaluteScienzaVolontariato/Solidarietà/Non profit

9 comunicati stampa

Guarda tutti i comunicati
24/09/2025
Volontariato/Solidarietà/Non profit
Industria
Salute
Igiene alimentare
Biotecnologia
Medicina - Varie
Farmaceutica
Cure Rare Disease Secures FDA Orphan Drug Designation for Investigational Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type R9 (LGMD2i/R9)
Fonte
Cure Rare Disease
Emittente
Business Wire
1.00
0
24/06/2025
Scienza
Igiene alimentare
Biotecnologia
Salute
Farmaceutica
Sanità
Volontariato/Solidarietà/Non profit
Industria
Cure Rare Disease Receives FDA Feedback on Limb-Girdle 2i/R9 Gene Therapy Program Following Successful Pre-IND Meeting
Fonte
Cure Rare Disease
Emittente
Business Wire
1.00
0
23/06/2025
Scienza
Igiene alimentare
Biotecnologia
Salute
Farmaceutica
Sanità
Volontariato/Solidarietà/Non profit
Industria
Cure Rare Disease Receives FDA Feedback on Limb-Girdle 2i/R9 Gene Therapy Program Following Successful Pre-IND Meeting
Fonte
Cure Rare Disease
Emittente
Business Wire
1.00
0
09/06/2025
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Volontariato/Solidarietà/Non profit
Mercato del lavoro
Cure Rare Disease Welcomes New Scientific and Strategic Leaders to Advance Therapies for Ultra-Rare Conditions
Fonte
Cure Rare Disease
Emittente
Business Wire
1.00
0
14/05/2025
Volontariato/Solidarietà/Non profit
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Medicina - Varie
Cure Rare Disease Receives Orphan Drug Designation from FDA for Investigational Therapy Targeting Spinocerebellar Ataxia Type 3 (SCA3)
Fonte
Cure Rare Disease
Emittente
Business Wire
1.00
0
03/04/2025
Multimedialità
Volontariato/Solidarietà/Non profit
Eventi
Biotecnologia
Sport
Salute
Famiglia
Vetrine/Shopping
Associazioni/Professionisti
Scienza
Infanzia
We Row For William: 157 Miles, One Nonstop Journey of Hope
Fonte
Cure Rare Disease
Emittente
Business Wire
1.00
0
06/02/2025
Biotecnologia
Salute
Scienza
Volontariato/Solidarietà/Non profit
Cure Rare Disease Awarded $5.69 Million CIRM Grant to Advance Gene Therapy for Spinocerebellar Ataxia Type 3
Fonte
Cure Rare Disease
Emittente
Business Wire
1.00
0
18/12/2024
Cure Rare Disease Appoints Brittany Stineman as Chief Advancement Officer
Fonte
Cure Rare Disease
Emittente
Business Wire
1.00
0
18/12/2024
Cure Rare Disease Appoints Brittany Stineman as Chief Advancement Officer
Fonte
Cure Rare Disease
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0